info@seagull-health.com
SeagullHealth
语言:
search
new
What Are the Indications for Qutenza (Capsaicin Patch)?
503
Article source: Seagull Pharmacy
Nov 17, 2025

Qutenza (Capsaicin Patch) is a therapeutic medication approved by the U.S. Food and Drug Administration (FDA), providing an innovative treatment option for patients with specific types of neuropathic pain. Administered topically, this medication acts directly on the painful area to exert its unique analgesic effect.

What Are the Indications for Qutenza (Capsaicin Patch)?

Postherpetic Neuralgia (PHN)

Qutenza is explicitly approved for the treatment of postherpetic neuralgia (PHN) in adults.

PHN is a common complication following herpes zoster virus infection, characterized by persistent neuropathic pain that significantly impairs patients’ quality of life.

Clinical trial data show that this medication demonstrates favorable efficacy in the treatment of PHN, effectively alleviating patients’ pain symptoms.

Diabetic Peripheral Neuropathy (DPN)

The medication is also indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults, particularly symptoms affecting the feet.

Population Restrictions for Use

It is important to emphasize that Qutenza is for adult use only.

No studies on its efficacy have been conducted in patients under 18 years of age, and it is not recommended for children or adolescents.

Specifications and Properties of Qutenza (Capsaicin Patch)

Basic Specification Parameters

Qutenza has a standardized size: each patch measures 14 cm × 20 cm, with a total area of 280 cm².

Active Ingredient Content

Each Qutenza patch contains 8% capsaicin as the active ingredient.

Specifically, it contains 640 micrograms of capsaicin per square centimeter, with a total capsaicin content of 179 milligrams per patch.

This concentration has been validated in clinical trials to ensure efficacy while controlling the risk of adverse reactions.

Physical Structure Features

The patch adopts a precision layered structure design, consisting of the following components:

Backing layer: Serves as the foundational support structure of the patch.

Medicated adhesive layer: Contains capsaicin, the active ingredient.

Protective release liner: Transparent and unprinted, with a diagonal cut for easy application.

Auxiliary Supporting Products

Qutenza is accompanied by a dedicated cleansing gel, used to remove residual capsaicin from the skin after treatment.

The cleansing gel is packaged in a 50-gram tube, ensuring sufficient quantity for the entire treatment process.

Storage Methods for Qutenza (Capsaicin Patch)

Storage Environment Requirements

Qutenza should be stored at a temperature between 20°C and 25°C (equivalent to 68°F and 77°F).

Short-term temperature fluctuations between 15°C and 30°C (59°F and 86°F) are permitted but should be minimized as much as possible.

Packaging Integrity

The medication is stored in a sealed aluminum foil bag, which should only be opened at the time of use.

During storage, the packaging must be kept intact; if torn or damaged, the patch must not be used.

Usage Precautions

Maintain sealing: Before use, the patch must always remain in the sealed bag.

Contamination prevention: All items that have come into contact with the medication should be disposed of immediately after use.

Safety protection: Operators should wear nitrile gloves; the use of masks and safety goggles is recommended.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Recommended Articles
Purchase Channels for Qutenza (Capsaicin Patch)
Qutenza (Capsaicin Patch) is a topical patch containing 8% capsaicin, classified as a TRPV1 channel agonist. In July 2020, this medication was approved by the U.S. FDA for the treatment of foot neural...
What Are the Side Effects of Epalrestat?
Epalrestat is a selective aldose reductase inhibitor. Since its approval in Japan in 1992, it has been mainly used for the treatment of diabetic peripheral neuropathy. Similar to other medications, Ep...
What are the Precautions for Taking Epalrestat?
Epalrestat is an aldose reductase inhibitor. Since its approval in Japan in 1992, it has been widely used as an adjuvant treatment for diabetic peripheral neuropathy.What are the Precautions for Takin...
Dosage and Administration of Epalrestat: Recommended Dosage
Epalrestat is a selective aldose reductase inhibitor. Since its approval in Japan in 1992, it has become an important therapeutic agent for diabetic peripheral neuropathy.Dosage and Administration of ...
Dosage and Administration of Qutenza (Capsaicin Patch)
Qutenza (Capsaicin Patch) is an FDA-approved topical medication for the treatment of postherpetic neuralgia (PHN) and neuropathic pain associated with diabetic peripheral neuropathy (DPN). Its unique ...
What Are the Precautions for Using Qutenza (Capsaicin Patch)?
Qutenza (Capsaicin Patch) is a transdermal drug delivery system containing 8% capsaicin (640 micrograms per square centimeter), which was first approved in the United States in 2009. As a TRPV1 channe...
Side Effects of Qutenza (Capsaicin Patch)
Qutenza (Capsaicin Patch) is a topical patch system containing 8% capsaicin, indicated for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and diabetic peripheral neurop...
Purchase Channels for Xphozah (Tenapanor)
Xphozah (Tenapanor) is a sodium-hydrogen exchanger 3 (NHE3) inhibitor with tenapanor hydrochloride as the active ingredient. First approved in the United States in 2019, this medication is primarily u...
Related Articles
Dosage and Administration, Recommended Dosage of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor, offering a precision treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation...
What Are the Indications for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted therapy medication that plays an important role in the treatment of non-small cell lung cancer associated with specific gene mutations. As a MET kinase inhibitor, i...
What Are the Purchase Channels for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a highly selective MET inhibitor that has demonstrated significant efficacy in patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutat...
Adverse Reactions of Ivosidenib (Tibsovo)
Ivosidenib (Tibsovo) is an isocitrate dehydrogenase 1 (IDH1) inhibitor, primarily indicated for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and cholangiocarcinoma...
What Are the Precautions for Using Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is a targeted therapy medication primarily indicated for the treatment of patients with malignant hematologic diseases harboring specific gene mutations.What Are the Precautions f...
Dosage and Administration, Recommended Dosage of Ivosidenib (Tibsovo)
Ivosidenib (Tibsovo) is a targeted isocitrate dehydrogenase 1 (IDH1) inhibitor that demonstrates significant value in the treatment of malignant tumors with specific gene mutations.Dosage and Administ...
What Are the Indications for Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is an oral isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with various malignant tumors harboring specific IDH1 gene mutations. By inhibiting the activity of m...
What Are the Purchase Channels for Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is an important targeted therapy drug against IDH1 mutations, demonstrating significant efficacy in diseases such as acute myeloid leukemia and cholangiocarcinoma. For patients in...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved